Drug Trial Radar · NCT06082323
A Single and Multiple Ascending Dose Trial of LT-002-158 Tablets in Healthy Adult Volunteers
Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
150
Actual
Start
Jun 13, 2024
Primary completion
Nov 25, 2025
Study completion Nov 25, 2025
Sponsor
- Lead sponsor
- Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
LT-002-158 is an oral IRAK4 protein degrader being developed for the treatment of autoimmune disease and inflammation including Hidradenitis Suppurativa and Atopic Dermatitis. This first-in-human (FIH) study will characterize the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of a single ascending dose and multiple ascending doses of LT-002-158 in healthy volunteers. The effects of food on the pharmacokinetics of LT-002-158 will also be assessed in healthy volunteers.
Conditions
- Healthy Volunteer
- Hidradenitis Suppurativa
- Atopic Dermatitis
Interventions
LT-002-158/Placebo oral tablet(s)Drug
Single ascending dose escalation and multiple ascending dose escalation study followed by an evaluation of food effects on absorption Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and tolerability of LT-002-158 following single dose in HVsTime frame: up to 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Xuhui Distric Central Hospital
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.